$720 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 75 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FIVERR INTL LTDnote 11/0 | $3,900,000 | +3.0% | 4,951,000 | 0.0% | 0.54% | +33.6% | ||
| RZLT | REZOLUTE INC | $3,167,000 | -15.2% | 1,155,897 | 0.0% | 0.44% | +10.3% | |
| PMVP | PMV PHARMACEUTICALS INC | $2,235,000 | -16.5% | 187,800 | 0.0% | 0.31% | +8.4% | |
| MGIC | MAGIC SOFTWARE ENTERPRISES Lord | $1,265,000 | -12.5% | 81,293 | 0.0% | 0.18% | +13.5% | |
| WIX COM LTDnote 8/1 | $591,000 | +4.4% | 700,000 | 0.0% | 0.08% | +34.4% | ||
| NICE SYS INCnote 1.250% 1/1 | $571,000 | -2.9% | 250,000 | 0.0% | 0.08% | +25.4% | ||
| ONCR | ONCORUS INC | $459,000 | -32.6% | 540,258 | 0.0% | 0.06% | -12.3% | |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $271,000 | +32.8% | 100,000 | 0.0% | 0.04% | +72.7% | |
| ARBE ROBOTICS LTDordinary shares | $259,000 | +9.3% | 43,165 | 0.0% | 0.04% | +44.0% | ||
| OTONOMO TECHNOLOGIES LTDordinary shares | $111,000 | -74.2% | 391,863 | 0.0% | 0.02% | -67.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 39 | Q2 2024 | 8.4% |
| MERCK & CO INC NEW | 38 | Q2 2024 | 8.4% |
| NICE Systems Ltd | 30 | Q2 2024 | 4.4% |
| BIOGEN INC | 29 | Q2 2024 | 6.7% |
| PFIZER INC | 28 | Q2 2024 | 9.2% |
| SAREPTA THERAPEUTICS INC | 28 | Q2 2024 | 3.2% |
| JOHNSON & JOHNSON | 27 | Q2 2024 | 8.0% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| SYNDAX PHARMACEUTICALS INC | 25 | Q2 2024 | 3.9% |
| ASTRAZENECA PLC | 24 | Q2 2024 | 7.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Skye Bioscience, Inc. | February 08, 2024 | 1,301,518 | 5.4% |
| Inozyme Pharma, Inc. | February 05, 2024 | 1,562,907 | 2.5% |
| Jasper Therapeutics, Inc. | February 05, 2024 | 7,130,625 | 6.4% |
| Praxis Precision Medicines, Inc. | February 05, 2024 | 328,986 | 3.7% |
| ProMIS Neurosciences Inc. | February 05, 2024 | 1,892,474 | 10.0% |
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| SC 13G | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.